Skip to main content
Download PDF
- Main
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- Lin, Luping;
- Sabnis, Amit J;
- Chan, Elton;
- Olivas, Victor;
- Cade, Lindsay;
- Pazarentzos, Evangelos;
- Asthana, Saurabh;
- Neel, Dana;
- Yan, Jenny Jiacheng;
- Lu, Xinyuan;
- Pham, Luu;
- Wang, Mingxue M;
- Karachaliou, Niki;
- Cao, Maria Gonzalez;
- Manzano, Jose Luis;
- Ramirez, Jose Luis;
- Torres, Jose Miguel Sanchez;
- Buttitta, Fiamma;
- Rudin, Charles M;
- Collisson, Eric A;
- Algazi, Alain;
- Robinson, Eric;
- Osman, Iman;
- Muñoz-Couselo, Eva;
- Cortes, Javier;
- Frederick, Dennie T;
- Cooper, Zachary A;
- McMahon, Martin;
- Marchetti, Antonio;
- Rosell, Rafael;
- Flaherty, Keith T;
- Wargo, Jennifer A;
- Bivona, Trever G
Published Web Location
https://doi.org/10.1038/ng.3218Abstract
Trever Bivona and colleagues show that the Hippo pathway effector YAP promotes resistance to RAF and MEK inhibitor therapy in multiple types of BRAF-mutant tumors. The findings suggest that combined suppression of YAP and RAF-MEK signaling might enhance treatment response and prevent drug resistance.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.